Apellis Pharmaceuticals Stock News

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

Related Stocks: INBX , IMTX , CMPS , GOSS , BCAB , CRVS , BCYC , APLS , ZNTL , AYLA , WVE , MCRB , ALEC , ANVS , CGEM , CCXI , CHAQ.U , IMAB ,

Related Stocks: XLRN , APLS , FOLD , PMVP , RNA , AADI , KYMR , DICE , BIIB , NUVL , TNGX , CNST , RLMD , OLMA , CNTA , BCTG , ADAP ,

Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Complement 3 Glomerulopathy (C3G) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering.

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q3 2021 Results - Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts were ac

Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal Produc

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that th

WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the compan

A drop in the overall market provides an opportunity for investors to pounce.

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data from th